XM does not provide services to residents of the United States of America.
B
B

BillerudKorsnas

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Billerud Decides To Not Proceed With Plans To Convert Its Escanaba Mill To Cartonboard Production

BRIEF-Billerud Decides To Not Proceed With Plans To Convert Its Escanaba Mill To Cartonboard Production May 21 (Reuters) - Billerud AB (publ) BILL.ST : BILLERUD DECIDES ON A NEW DIRECTION TO TRANSFORM PRODUCTION IN THE US TOWARDS PACKAGING MATERIALS BOD HAS DECIDED TO NOT PROCEED WITH PLANS TO CONVERT ITS ESCANABA MILL TO CARTONBOARD PRODUCTION WIL
B

CEO Of Billerud Allocates 21,989 Shares At Price About SEK 99 Per Share On May 15

BRIEF-CEO Of Billerud Allocates 21,989 Shares At Price About SEK 99 Per Share On May 15 May 16 (Reuters) - Billerud AB (publ) BILL.ST : FINANSINSPEKTIONEN: CEO OF BILLERUD AB IVAR VATNE ALLOCATES 21,989 SHARES AT PRICE ABOUT SEK 99 PER SHARE ON MAY 15 Further company coverage: BILL.ST (Gdansk Newsroom)
B

Adidas, HSBC, Renishaw

EUROPE RESEARCH ROUNDUP-Adidas, HSBC, Renishaw May 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, HSBC and Renishaw on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : Wedbush raises target price to EUR 233 from EUR 200 * Darktrace DARK.L : HSBC raises target price to 620p from 540p * Essity AB (Publ) ESSITYb.ST : HSBC resumes with buy rating; price target SEK 330 * HSBC HSBA.L : Berenberg raises target price to 830p from 80
A
A
A
A
B
B
B
C
C
E
E
F
F
H
H
H
K
L
M
P
R
S
S
S
T
E
G
N
S
U

Billerud's Outlook For Q2: Maintenance Shutdowns Estimated To Cost SEK 525 Million

BRIEF-Billerud's Outlook For Q2: Maintenance Shutdowns Estimated To Cost SEK 525 Million April 24 (Reuters) - Billerud AB (publ) BILL.ST : OUTLOOK FOR Q2: MAINTENANCE SHUTDOWNS ESTIMATED TO HAVE A COST IMPACT OF SEK 525 MILLION OUTLOOK FOR Q2: INCREASED SALES PRICES EXPECTED TO OFFSET HIGHER INPUT COSTS MAINLY DRIVEN BY HIGHER PULPWOOD PRICES DESPITE HEADWINDS OF HIGHER COSTS FOR ENERGY, LOGISTICS AND FIBER IN EUROPE, GROUP'S EBITDA MARGIN STRENGTHENED TO 11% MARKET SENTIMENT CLEARLY IMPROVED DU
B

AstraZeneca, Carl Zeiss Meditec, Luceco

EUROPE RESEARCH ROUNDUP-AstraZeneca, Carl Zeiss Meditec, Luceco April 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Carl Zeiss Meditec and Luceco, on Friday. HIGHLIGHTS * AstraZeneca AZN.L : HSBC raises target price to 12,950p from 12,150p * Carl Zeiss Meditec AG AFXG.DE : JP Morgan raises target price to EUR 70 from EUR 59 * Ipsen SA IPN.PA : RBC raises target price to EUR 127 from EUR 124 * Luceco Plc LUCEL.L : P
A
A
A
B
B
C
E
G
H
I
K
S
S
S
S
W
A
A
A
A
A
A
B
D
S
U
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.